Surepulse.

Wireless neonatal heart rate monitors.

SurePulse Medical is developing highly accurate heart rate measuring technology designed specifically for babies who need stabilisation or resuscitation at birth. SurePulse can help reduce the time babies spend in neonatal intensive care and reduce costs for healthcare organisations. The company is a joint venture between the University of Nottingham and Tioga Ltd.

Technology & Products.

The Surepulse VS is a neonatal heart rate monitor containing a sensor mounted in a disposable cap which uses reflected light to monitor heart rhythms. The cap design is fully compatible with existing clinical practice. Data is wirelessly transmitted to a rechargeable handset to allow complete flexibility of use by medical staff. Design of the hat and cap are the subject of a patent application. Surepulse has successfully obtained a CE mark for the Surepulse VS device. Volume production tooling has also been completed.

The Market.

Currently 10% of births require some form of resuscitation. That equates to 80,000 births per annum in the UK, 400,000 in the USA and 13.5 million worldwide. However, the standard of care for post-birth heart rate monitoring still relies on use of a stethoscope. There is a clear requirement for a more reliable and less error-prone approach across the globe.

Business Model.

The company will manufacture the device using a number of partner companies and look to form relationships with healthcare equipment distributers to sell into healthcare systems worldwide.

Fundraising to july 2020.

The company has previously raised £1.75m. A £1m fund raising round is currently underway.

Team.

Chairman: Russell Hoyle. Considerable leadership experience. Other roles include Chairman of Tioga Ltd and Special Partner at Vitruvian Partners LLP. Previously Chairman of Inspired Gaming Group PLC.
CEO: Dr James Carpenter. An electronic engineer, he has successfully led the company since its foundation in 2014. Considerable research experience in development of medical devices for blood flow and heart rate analysis.
Research Director: Professor Barry Hayes-Gill. 30 years’ experience ofdevelopingelectronicmedicaldevicesfrombenchtobedside. Co- founder of Monica Healthcare which fully commercialised a foetal heart rate monitor.

Contact: Andrew Naylor, CEO, Nottingham Technology Ventures. andrew.naylor@nottingham.ac.uk https://www.surepulsemedical.com/

KEY FEATURES.

9C12A659-F601-4D82-B0B7-58B26B8FB50E

Office space

In oculis quidem se esse vult, summumque malum et, quantum.

Lab space

In oculis quidem se esse vult, summumque malum et, quantum.

Business support

In oculis quidem se esse vult, summumque malum et, quantum.

8BA7CC87-ADB9-4E9E-B6B0-0F609EA2D3A9

Meeting rooms

In oculis quidem se esse vult, summumque malum et, quantum.

Virtual tenancy

In oculis quidem se esse vult, summumque malum et, quantum.

Hot desks

In oculis quidem se esse vult, summumque malum et, quantum.

IP Status

In oculis quidem se esse vult, summumque malum et, quantum.

Opportunity

In oculis quidem se esse vult, summumque malum et, quantum.

Application areas

In oculis quidem se esse vult, summumque malum et, quantum.

Management Team

In oculis quidem se esse vult, summumque malum et, quantum.

27D4EAE4-6FBF-4578-BCBD-4F102E515086

Investment Stage

In oculis quidem se esse vult, summumque malum et, quantum.

1EEFF807-B5A2-4190-89BC-DE59BFF00B15

Investors

In oculis quidem se esse vult, summumque malum et, quantum.

Technology Readiness

In oculis quidem se esse vult, summumque malum et, quantum.

Make An Enquiry.